This work aimed to report real‐world outcomes from the use of SBRT to treat ADT naïve, PSMA‐detected oligometastatic prostate cancer (OPCa) and to assess disease and treatment characteristics in this heterogeneous population intersect or impact treatment response. Here, FOLH1 is linked to prostate cancer.